Histogenics successfully completed consultations with Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage defects. Histogenics has nearly completed enrollment in a 245-patient Phase III clinical trial conducted under a Special Protocol Assessment with FDA, and seeks to leverage its U.S. clinical, preclinical and cGMP data on NeoCart into ex-U.S. markets.
Shortly after reacquiring Japanese rights for NeoCart from Purpose Co. in 2Q16, Histogenics initiated preparatory pre-consultations with the PMDA for the regulatory process. In 1Q17, PMDA agreed that the ongoing Phase III clinical trial with its 1-year primary endpoint could provide sufficient evidence of safety and effectiveness for the full Marketing and Manufacturing Authorization in Japan.
Furthermore, PMDA agreed that a 30-patient, 1-year confirmatory clinical trial in Japanese patients, comparing NeoCart to microfracture, would be sufficient for applying for full Marketing and Manufacturing Authorization in Japan.
Histogenics estimates 200,000 procedures annually in Japan for patients suffering from pain associated with cartilage defects in the knee.
Sources: Histogenics Corporation; ORTHOWORLD Inc.
Histogenics successfully completed consultations with Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage defects. Histogenics has nearly completed enrollment in a 245-patient Phase III clinical trial conducted under a Special Protocol...
Histogenics successfully completed consultations with Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage defects. Histogenics has nearly completed enrollment in a 245-patient Phase III clinical trial conducted under a Special Protocol Assessment with FDA, and seeks to leverage its U.S. clinical, preclinical and cGMP data on NeoCart into ex-U.S. markets.
Shortly after reacquiring Japanese rights for NeoCart from Purpose Co. in 2Q16, Histogenics initiated preparatory pre-consultations with the PMDA for the regulatory process. In 1Q17, PMDA agreed that the ongoing Phase III clinical trial with its 1-year primary endpoint could provide sufficient evidence of safety and effectiveness for the full Marketing and Manufacturing Authorization in Japan.
Furthermore, PMDA agreed that a 30-patient, 1-year confirmatory clinical trial in Japanese patients, comparing NeoCart to microfracture, would be sufficient for applying for full Marketing and Manufacturing Authorization in Japan.
Histogenics estimates 200,000 procedures annually in Japan for patients suffering from pain associated with cartilage defects in the knee.
Sources: Histogenics Corporation; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.